Foghorn Therapeutics annual net debt
2019
2020
2021
2022
2023
2024
2025
Foghorn Therapeutics Net Debt Growth & History (FHTX)
Foghorn Therapeutics's net debt was −$39.6M for fiscal 2025.
View full Foghorn Therapeutics company overviewFoghorn Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$39.6M | −$21.3M | — |
| 2024 | 2024-12-31 | −$18.3M | $16.9M | — |
| 2023 | 2023-12-31 | −$35.3M | −$34.6M | — |
| 2022 | 2022-12-31 | −$707,000 | $42.1M | — |
| 2021 | 2021-12-31 | −$42.8M | −$32.0M | — |
| 2020 | 2020-12-31 | −$10.8M | −$12.4M | — |
| 2019 | 2019-12-31 | $1.6M | — | — |
Foghorn Therapeutics quarterly net debt
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$25.0M | $23.9M | — |
| Q1 2026 | 2026-03-31 | −$45.7M | −$19.5M | — |
| Q4 2025 | 2025-12-31 | −$39.6M | −$21.3M | — |
| Q3 2025 | 2025-09-30 | −$66.8M | −$48.2M | — |
| Q2 2025 | 2025-06-30 | −$48.9M | $52.9M | — |
| Q1 2025 | 2025-03-31 | −$26.2M | $10.1M | — |
| Q4 2024 | 2024-12-31 | −$18.3M | $16.9M | — |
| Q3 2024 | 2024-09-30 | −$18.6M | $4.6M | — |
| Q2 2024 | 2024-06-30 | −$101.8M | −$92.1M | — |
| Q1 2024 | 2024-03-31 | −$36.3M | −$35.5M | — |
| Q4 2023 | 2023-12-31 | −$35.3M | −$34.6M | — |
| Q3 2023 | 2023-09-30 | −$23.2M | $11.2M | — |
| Q2 2023 | 2023-06-30 | −$9.8M | −$3.4M | — |
| Q1 2023 | 2023-03-31 | −$802,000 | $156.3M | — |
| Q4 2022 | 2022-12-31 | −$707,000 | $42.1M | — |
| Q3 2022 | 2022-09-30 | −$34.4M | −$56.6M | — |
| Q2 2022 | 2022-06-30 | −$6.4M | $36.8M | — |
| Q1 2022 | 2022-03-31 | −$157.1M | −$173.2M | — |
| Q4 2021 | 2021-12-31 | −$42.8M | −$32.0M | — |
| Q3 2021 | 2021-09-30 | $22.2M | $25.9M | — |
| Q2 2021 | 2021-06-30 | −$43.2M | — | — |
| Q1 2021 | 2021-03-31 | $16.2M | — | — |
| Q4 2020 | 2020-12-31 | −$10.8M | −$12.4M | — |
| Q3 2020 | 2020-09-30 | −$3.7M | — | — |
| Q4 2019 | 2019-12-31 | $1.6M | — | — |
Foghorn Therapeutics net debt trends
Over the last five fiscal years, Foghorn Therapeutics's net debt decreased from −$10.8M to −$39.6M, a change of −$28.8M. The latest reported quarter, Q2 2026, shows −$25.0M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Foghorn Therapeutics source filings ↗